알츠하이머병 진단 및 치료 시장 : 세계 예측(2026-2032년)

The Alzheimer's Disease Diagnostics & Therapeutics Market is projected to grow by USD 17.58 billion at a CAGR of 9.82% by 2032.

Alzheimer's disease diagnostics and therapeutics are entering a decisive phase as healthcare systems confront rising dementia prevalence, earlier clinical presentation, and the growing need for evidence-based disease modification. The field spans cognitive assessment, biomarker-based diagnostics, neuroimaging, cerebrospinal fluid testing, blood-based biomarkers, digital cognitive tools, amyloid- and tau-targeted therapies, symptomatic treatments, care-support technologies, and emerging approaches focused on inflammation, synaptic health, vascular risk, and neuroprotection. According to the World Health Organization, more than 55 million people live with dementia globally, and Alzheimer's disease is the most common cause, reinforcing the urgency of timely diagnosis and effective care pathways. Regulatory approvals of anti-amyloid monoclonal antibodies in select markets have intensified demand for earlier detection, patient stratification, treatment monitoring, and multidisciplinary care pathways. At the same time, safety requirements, infusion capacity, biomarker confirmation, reimbursement scrutiny, and equitable access remain central constraints. The industry is shifting from a late-stage symptom-management model toward an integrated Alzheimer's care continuum that prioritizes timely diagnosis, biomarker validation, real-world evidence, and coordinated therapeutic decision-making.

Transformative Shifts in the Alzheimer's Disease Landscape

The Alzheimer's disease landscape is being transformed by the convergence of biomarker science, precision neurology, and health-system redesign. Blood-based biomarker research, particularly assays associated with phosphorylated tau, amyloid pathology, and neurodegeneration, is accelerating clinical pathways that historically depended on specialist evaluation, positron emission tomography, or cerebrospinal fluid analysis. Advanced imaging continues to support diagnostic confirmation and therapy eligibility, while digital cognitive assessments and remote monitoring tools are improving longitudinal disease tracking. Therapeutically, the transition from symptomatic-only care to disease-modifying strategies is reshaping clinical protocols, requiring amyloid confirmation, risk assessment for amyloid-related imaging abnormalities, and post-treatment surveillance. These shifts are also increasing the importance of trained memory-care specialists, infusion infrastructure, radiology access, payer alignment, and patient education. The most durable progress is expected from integrated models that combine accurate diagnosis, appropriate therapeutic selection, caregiver support, and standardized outcome measurement across real-world settings.

Cumulative Impact of Artificial Intelligence on Alzheimer's Care

Artificial intelligence is becoming a cumulative enabler across Alzheimer's disease diagnostics and therapeutics by improving signal detection, workflow efficiency, and evidence generation. In diagnostics, AI-enabled analysis of magnetic resonance imaging, positron emission tomography, speech patterns, electronic health records, wearable data, and digital cognitive testing can support earlier risk identification and more consistent longitudinal monitoring. In therapeutics, machine learning is being applied to patient stratification, trial enrichment, target discovery, safety surveillance, and prediction of disease progression. AI is particularly relevant where clinical capacity is limited, as decision-support tools can help prioritize referrals and standardize evaluation pathways. However, responsible adoption requires validated datasets, transparent algorithms, bias mitigation, data privacy safeguards, clinical oversight, and alignment with medical-device and software regulatory requirements. The cumulative impact of AI will depend less on standalone tools and more on how effectively health systems embed validated intelligence into neurology workflows, biomarker interpretation, patient engagement, and real-world evidence collection.

Key Regional Insights Across Global Alzheimer's Diagnostics and Therapeutics

Asia-Pacific is characterized by rapidly aging populations, expanding neurology capacity, and growing interest in scalable dementia screening, with Japan, China, South Korea, Australia, and India playing distinct roles in clinical research, diagnostic adoption, and care model development. Japan's long-standing national dementia policy focus, China's expanding hospital and research infrastructure, and India's need for low-cost community screening collectively make the region highly diverse in Alzheimer's disease diagnostics and therapeutics readiness. North America remains a leading region for advanced Alzheimer's diagnostics and therapeutics due to established specialist networks, biomarker research infrastructure, regulatory pathways for disease-modifying therapies, and strong use of real-world evidence; however, access remains shaped by reimbursement policies, rural neurology shortages, and capacity for infusion and imaging. Latin America faces increasing dementia burden alongside uneven access to specialists, neuroimaging, and biomarker testing, making primary-care education, public awareness, and cost-effective diagnostic pathways critical. Europe benefits from mature dementia strategies in several countries, strong academic neurology networks, and evolving health technology assessment processes, while variability in reimbursement, PET capacity, and national treatment guidelines influences adoption. The Middle East is advancing dementia care through specialist-center development, hospital infrastructure investment, and growing attention to aging-related neurological disease, particularly in high-income Gulf states. Africa faces the most significant access constraints, including limited dementia awareness, scarce specialist capacity, and restricted availability of advanced diagnostics, creating a strong need for community-based screening, workforce training, and culturally adapted cognitive assessment tools.

Key Group Insights Shaping Alzheimer's Disease Care Pathways

ASEAN countries are strengthening dementia awareness and geriatric care capacity, but wide differences in healthcare financing, specialist availability, and diagnostic infrastructure make scalable cognitive screening and referral networks essential for Alzheimer's disease management. The GCC is building advanced healthcare systems with growing neurology and imaging capabilities, and its aging populations are increasing the policy relevance of memory clinics, caregiver support, and specialist-led treatment pathways. The European Union provides an important regulatory and research environment for Alzheimer's diagnostics and therapeutics, with cross-border collaboration, data governance frameworks, and health technology assessment processes influencing the adoption of biomarker testing and novel therapies. BRICS countries combine substantial population need with diverse healthcare-system maturity; China and India are central to future diagnostic access because of demographic scale, while Brazil, Russia, and South Africa face distinct challenges related to service distribution, affordability, and specialist concentration. G7 countries are at the forefront of clinical guideline development, regulatory review, advanced imaging use, biomarker validation, and real-world evidence generation, though affordability, treatment monitoring, and equitable access remain ongoing concerns. NATO countries overlap significantly with high-income health systems in North America and Europe, where preparedness for dementia care increasingly intersects with workforce planning, digital health infrastructure, and resilience of specialist services.

Key Country Insights in Alzheimer's Disease Diagnostics and Therapeutics

The United States has a highly active Alzheimer's disease ecosystem supported by specialist centers, biomarker research, regulatory activity, and clinical trial infrastructure, while implementation challenges include payer coverage, treatment monitoring, rural access, and infusion capacity. Canada emphasizes publicly funded healthcare delivery, memory-clinic networks, and evidence-based assessment, with regional differences affecting access to advanced imaging and specialist consultation. Mexico and Brazil face rising dementia needs and uneven specialist distribution, making awareness campaigns, primary-care training, and affordable diagnostic approaches central to improved Alzheimer's care. The United Kingdom has established dementia policy experience and strong academic research capabilities, although diagnostic backlogs and health-service capacity influence the speed of clinical adoption. Germany, France, Italy, and Spain maintain robust neurology networks, aging-population policy focus, and advanced hospital infrastructure, with national reimbursement and health technology assessment decisions shaping access to biomarker confirmation and newer therapeutics. Russia has significant neurological care capacity in major urban centers, but geographic variation affects diagnostic consistency and access to advanced modalities. China is expanding dementia research, hospital capacity, and biomarker interest in response to rapid population aging, while India's large population and variable healthcare access heighten the importance of low-cost screening, caregiver education, and scalable referral systems. Japan is one of the most advanced aging societies, with high policy attention to dementia, strong clinical research activity, and established demand for early detection and care coordination. Australia combines dementia strategy, academic research, and specialist care networks with ongoing challenges in rural and remote access. South Korea is advancing national dementia initiatives, digital health adoption, and specialist services, supporting earlier identification and structured Alzheimer's disease management.

Actionable Recommendations for Alzheimer's Disease Industry Leaders

Industry leaders should prioritize integrated Alzheimer's care models that connect screening, biomarker confirmation, specialist evaluation, therapy eligibility, safety monitoring, and caregiver support. Diagnostic developers should focus on clinically validated, scalable biomarker tools that can reduce referral delays while maintaining high analytical performance and clear interpretation standards. Therapeutic stakeholders should align product strategies with real-world treatment workflows, including imaging capacity, infusion logistics, adverse-event monitoring, and evidence requirements for reimbursement. Health technology teams should deploy AI and digital cognitive tools only after rigorous validation across diverse populations to reduce bias and improve clinical trust. Providers and payers should collaborate on pathways that identify appropriate patients earlier, avoid unnecessary testing, and support shared decision-making. Policymakers should invest in dementia workforce development, public awareness, registries, and equitable access to memory-care services. Across the value chain, success will depend on demonstrating clinical utility, patient safety, operational feasibility, and measurable improvement in diagnostic confidence and care outcomes.

Research Methodology for Alzheimer's Disease Diagnostics and Therapeutics

This executive summary is developed using a structured secondary research approach grounded in verified public-domain evidence, including peer-reviewed medical literature, regulatory communications, clinical practice guidelines, public health sources, dementia policy documents, and recognized clinical research outputs. The methodology emphasizes triangulation across neurology, geriatrics, diagnostic science, digital health, and therapeutic development to ensure balanced interpretation of Alzheimer's disease diagnostics and therapeutics trends. Evidence was assessed for clinical relevance, regulatory credibility, geographic applicability, and consistency across authoritative sources. Particular attention was given to biomarker evolution, disease-modifying therapy requirements, artificial intelligence applications, regional healthcare capacity, and access considerations. The analysis avoids market sizing, market estimation, market share, and forecasting, focusing instead on qualitative industry dynamics, verified clinical developments, and actionable implications for healthcare stakeholders.

Conclusion: Advancing Alzheimer's Diagnosis, Treatment, and Care

Alzheimer's disease diagnostics and therapeutics are moving toward an era defined by earlier detection, biomarker-guided decision-making, AI-enabled workflow support, and carefully monitored disease-modifying treatment pathways. The greatest opportunities lie in translating scientific advances into accessible, equitable, and clinically reliable care models that work across specialist centers, community settings, and diverse regional health systems. While advanced therapies and biomarkers are changing expectations, their impact depends on diagnostic readiness, safety surveillance, reimbursement alignment, workforce training, and patient-centered communication. Stakeholders that combine validated diagnostics, responsible digital innovation, therapeutic evidence, and practical implementation strategies will be best positioned to improve Alzheimer's disease care. The sector's next phase will be measured not only by scientific progress but by the ability to deliver timely diagnosis, appropriate treatment, and sustained support for patients and caregivers.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Alzheimer's Disease Diagnostics & Therapeutics Market, by Product

• 7.1. Introduction
• 7.2. Diagnostics
  • 7.2.1. Biomarkers
    • 7.2.1.1. Blood-Based Biomarkers
    • 7.2.1.2. Cerebrospinal Fluid (CSF) Biomarkers
  • 7.2.2. Genetic Testing
  • 7.2.3. Imaging Techniques
    • 7.2.3.1. Computed Tomography (CT) Scans
    • 7.2.3.2. Electroencephalogram (EEG)
    • 7.2.3.3. Magnetic Resonance Imaging (MRI)
    • 7.2.3.4. Positron Emission Tomography (PET)
  • 7.2.4. Neuropsychological Testing
    • 7.2.4.1. Ascertain Dementia 8
    • 7.2.4.2. Mini-Mental State Exam
    • 7.2.4.3. Montreal Cognitive Assessment
    • 7.2.4.4. Neuropsychiatric Inventory Questionnaire
• 7.3. Therapeutics
  • 7.3.1. Combination Therapies
  • 7.3.2. Drug Therapies
  • 7.3.3. Non-Drug Therapies
    • 7.3.3.1. Behavioral Interventions
    • 7.3.3.2. Cognitive Stimulation Therapy

8. Alzheimer's Disease Diagnostics & Therapeutics Market, by Drug Class

• 8.1. Introduction
• 8.2. Cholinesterase Inhibitors
  • 8.2.1. Donepezil
  • 8.2.2. Galantamine
  • 8.2.3. Rivastigmine
• 8.3. Monoclonal Antibodies
  • 8.3.1. Aducanumab
  • 8.3.2. Donanemab
  • 8.3.3. Lecanemab
• 8.4. NMDA Receptor Antagonists

9. Alzheimer's Disease Diagnostics & Therapeutics Market, by Patient Demographics

• 9.1. Introduction
• 9.2. 65-74 Years
• 9.3. 75-84 Years
• 9.4. Above 85 Years
• 9.5. Below 65 Years

10. Alzheimer's Disease Diagnostics & Therapeutics Market, by Disease Stage

• 10.1. Introduction
• 10.2. Early-Stage Alzheimer's
• 10.3. Late-Stage Alzheimer's
• 10.4. Middle-Stage Alzheimer's

11. Alzheimer's Disease Diagnostics & Therapeutics Market, by End User

• 11.1. Introduction
• 11.2. Academic & Research Institutes
• 11.3. Diagnostic Centers
• 11.4. Homecare Settings
• 11.5. Hospitals & Clinics

12. Alzheimer's Disease Diagnostics & Therapeutics Market, by Distribution Channel

• 12.1. Introduction
• 12.2. Hospital Pharmacies
• 12.3. Online Pharmacies
• 12.4. Retail Pharmacies

13. Alzheimer's Disease Diagnostics & Therapeutics Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Alzheimer's Disease Diagnostics & Therapeutics Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Alzheimer's Disease Diagnostics & Therapeutics Market, by Country

• 15.1. United States
• 15.2. China
• 15.3. Germany
• 15.4. United Kingdom
• 15.5. Japan
• 15.6. Canada
• 15.7. India
• 15.8. Russia
• 15.9. Italy
• 15.10. France
• 15.11. Brazil
• 15.12. Mexico
• 15.13. Spain
• 15.14. South Korea
• 15.15. Australia

16. Competitive Landscape

• 16.1. Market Share Analysis, 2025
• 16.2. FPNV Positioning Matrix, 2025
• 16.3. Market Concentration Analysis, 2025
  • 16.3.1. Concentration Ratio (CR)
  • 16.3.2. Herfindahl Hirschman Index (HHI)
• 16.4. Recent Developments & Impact Analysis, 2025
• 16.5. Product Portfolio Analysis, 2025
• 16.6. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Abbvie Inc.
• 17.2. AC Immune SA
• 17.3. Alector, Inc.
• 17.4. Alzheon, Inc.
• 17.5. Amylyx Pharmaceuticals, Inc.
• 17.6. AstraZeneca PLC
• 17.7. Aurobindo Pharma Limited
• 17.8. Biogen Inc.
• 17.9. BioXcel Therapeutics Inc.
• 17.10. Bristol-Myers Squibb Company
• 17.11. Cognoptix Inc.
• 17.12. Corium Inc.
• 17.13. Danaher Corporation
• 17.14. Denali Therapeutics Inc.
• 17.15. Eisai Co., Ltd.
• 17.16. Eli Lilly and Company
• 17.17. F. Hoffmann-La Roche AG
• 17.18. GE Healthcare
• 17.19. Grifols, S.A.
• 17.20. H. Lundbeck A/S
• 17.21. Johnson & Johnson Services, Inc.
• 17.22. Lupin Limited
• 17.23. Luye Pharma Group Ltd.
• 17.24. Merck & Co. Inc.
• 17.25. Muna Therapeutics
• 17.26. Novartis AG
• 17.27. Quest Diagnostics Incorporated
• 17.28. Sanofi S.A.
• 17.29. Siemens Healthineers AG
• 17.30. Takeda Pharmaceutical Company Limited
• 17.31. TauRx Therapeutics Ltd.
• 17.32. Teva Pharmaceutical Industries Ltd.
• 17.33. Thermo Fisher Scientific Inc.
• 17.34. Voyager Therapeutics, Inc.
• 17.35. Zydus Lifesciences Limited